Central Venoplasty Emerging as a Life and limb Saving Technique for Critically ill Patients: Dr. Somyata Somendra Sharma

Successful treatment in three complex high-risk cases

Dr. Somyata shared that she recently performed this procedure successfully in three critically ill patients with a very high risk of bleeding.

The first patient was a 71-year-old woman undergoing long-term dialysis due to chronic kidney disease. She had low platelet counts and recurrent episodes of coughing up blood. She developed sudden, severe swelling in her left arm, and imaging revealed near-complete blockage of a major chest vein. Following venoplasty and stenting, the swelling reduced significantly within 12 hours, and she remained symptom-free during six months of follow-up.

The second case involved a 68-year-old man suffering from severe infection, septic shock, multi-organ failure, and kidney failure. He developed rapidly increasing swelling of the face and left arm, along with worsening breathlessness. Investigations confirmed extensive clot formation in the central veins. After undergoing Central Venoplasty, stenting, and targeted low-dose local thrombolysis, he showed marked improvement in swelling and breathing within 24 hours.

The third patient was a 66-year-old man with lung cancer, in whom cancer-related clot formation had caused severe blockage of the Superior Vena Cava and Innominate Vein. He presented with significant swelling of the face and both arms, accompanied by breathing difficulty. Following stent placement, the swelling improved dramatically within 12 hours, enabling him to proceed with further cancer treatment.

Dr. Somyata emphasized that the greatest advantage of Central Venoplasty is that it eliminates the need for major surgery while restoring blood flow rapidly. Most patients experience significant relief within hours of the procedure. When performed at the right time, Central Venoplasty is proving to be a safe and highly effective treatment option for patients with kidney disease, cancer, severe infections, and other complex conditions associated with a high risk of bleeding.

If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.